Updated Monitoring Guidance for the Chikungunya Live Attenuated Vaccine

To: Health Care Professionals in Niagara
From: Clinical Services Division, Niagara Region Public Health
Reference: Updated Monitoring Guidance for the Chikungunya Live Attenuated Vaccine
Date: April 30, 2026

A single-dose chikungunya live attenuated vaccine (CHIK-LAV, trade name IXCHIQ®) is authorized for use in Canada and is available for private purchase in Ontario.

This memo is intended for health care providers whose patients have:

Received CHIK-LAV, or
Requested a prescription for CHIK-LAV

Monitoring of CHIK-LAV Adverse Events Following Immunization (AEFIs)

According to the Committee to Advise on Tropical Medicine and Travel (CATMAT), global post-marketing surveillance has identified reports of serious adverse events following immunization with CHIK-LAV, primarily among individuals 65 years of age and older with underlying medical conditions

Health Care Provider Action

Report any suspected adverse events following immunization associated with CHIK-LAV through the usual AEFI reporting process
Encourage patients travelling to tropical and sub-tropical areas where arboviruses (e.g. chikungunya, dengue, Zika) are present to review travel advice and advisories by destination
Consult CATMAT’s guidance when assessing patients requesting a prescription for CHIK-LAV

More Information

AEFI Fact Sheet for Health Care Professionals
For health professionals: Chikungunya - Canada.ca
Niagara Region Public Health does not offer travel vaccine advice or fee-for-service travel vaccines. If your office does not offer these services, patients can visit participating pharmacies with a prescription as needed or attend a travel health clinic.
Call Public Health if you have questions related to the AEFI reporting process 905-688-8248 or 1-888-505-6074 ext. 7396